Gotham Asset Management LLC Lowers Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Gotham Asset Management LLC lessened its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 49.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 11,734 shares of the biotechnology company's stock after selling 11,661 shares during the quarter. Gotham Asset Management LLC's holdings in BioMarin Pharmaceutical were worth $771,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Merit Financial Group LLC acquired a new stake in shares of BioMarin Pharmaceutical during the 4th quarter valued at about $317,000. Swedbank AB boosted its position in BioMarin Pharmaceutical by 11.2% during the fourth quarter. Swedbank AB now owns 432,122 shares of the biotechnology company's stock worth $28,403,000 after purchasing an additional 43,593 shares in the last quarter. Rhumbline Advisers grew its holdings in BioMarin Pharmaceutical by 2.0% in the fourth quarter. Rhumbline Advisers now owns 556,255 shares of the biotechnology company's stock valued at $36,563,000 after purchasing an additional 11,025 shares during the period. Mediolanum International Funds Ltd acquired a new stake in BioMarin Pharmaceutical in the fourth quarter valued at approximately $1,237,000. Finally, Empowered Funds LLC purchased a new stake in shares of BioMarin Pharmaceutical in the fourth quarter valued at approximately $257,000. Hedge funds and other institutional investors own 98.71% of the company's stock.

BioMarin Pharmaceutical Trading Up 1.7%

Shares of BMRN opened at $59.27 on Monday. BioMarin Pharmaceutical Inc. has a 12-month low of $52.93 and a 12-month high of $94.85. The firm has a market capitalization of $11.37 billion, a P/E ratio of 26.94, a P/E/G ratio of 0.61 and a beta of 0.27. The firm has a 50-day moving average price of $63.63 and a 200 day moving average price of $65.04. The company has a current ratio of 5.33, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last posted its earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, beating the consensus estimate of $0.54 by $0.18. The company had revenue of $747.31 million for the quarter, compared to analyst estimates of $711.05 million. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. Sell-side analysts forecast that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current year.

Wall Street Analysts Forecast Growth

BMRN has been the topic of a number of recent analyst reports. Citigroup decreased their target price on BioMarin Pharmaceutical from $82.00 to $78.00 and set a "neutral" rating on the stock in a research report on Friday, May 2nd. The Goldman Sachs Group decreased their price objective on shares of BioMarin Pharmaceutical from $124.00 to $104.00 and set a "buy" rating on the stock in a report on Monday, May 5th. StockNews.com upgraded shares of BioMarin Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research report on Friday, April 25th. Wedbush reissued an "outperform" rating and set a $94.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Finally, Bank of America raised their price target on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the company a "buy" rating in a research note on Thursday, February 20th. Six equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, BioMarin Pharmaceutical currently has an average rating of "Moderate Buy" and an average price target of $93.45.

Insider Buying and Selling

In other news, CAO Erin Burkhart sold 1,295 shares of the company's stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.52, for a total value of $92,618.40. Following the transaction, the chief accounting officer now owns 16,955 shares of the company's stock, valued at $1,212,621.60. This represents a 7.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last three months, insiders sold 2,912 shares of company stock worth $202,244. Company insiders own 0.85% of the company's stock.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.